A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 440-441, 145-155
Abstract
No abstract availableKeywords
Funding Information
- CNRS
- ARC (3288)
- La ligue contre le cancer
- ANR
- Inserm
- Inca
- Conectus
- European COST (CM1105)
- ECOS Nord (279063)
This publication has 47 references indexed in Scilit:
- Designing a broad-spectrum integrative approach for cancer prevention and treatmentSeminars in Cancer Biology, 2015
- Complex Regulation of p73 Isoforms after Alteration of Amyloid Precursor Polypeptide (APP) Function and DNA Damage in NeuronsJournal of Biological Chemistry, 2011
- Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancerJournal of Cellular and Molecular Medicine, 2010
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsOncogene, 2009
- New trends for metal complexes with anticancer activityCurrent Opinion in Chemical Biology, 2008
- Antitumour metal compounds: more than theme and variationsDalton Transactions, 2007
- Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosisCell Death & Differentiation, 2007
- Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical ApproachesCurrent Medicinal Chemistry, 2005
- Toxicities of the platinum antineoplastic agentsExpert Opinion on Drug Safety, 2003
- The reaction of platinum(II) complexes with DNA. Kinetics of intrastrand crosslink formationin vitroNucleic Acids Research, 1991